Home > Insider Trading > Filing (0001209191-21-002621)

Filing Details

Accession Number:: 0001209191-21-002621
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-07 19:08:04
Reporting Period:: 2021-01-05

Accepted Time:: 2021-01-07 19:08:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1000694	Novavax Inc	NVAX	Biological Products, (No Disgnostic Substances) (2836)	222816046

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1468534	John Trizzino	C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878	Evp, Cmo And Cbo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-05	394	$27.00	5,481	No	4	M	Direct
Common Stock	Acquisiton	2021-01-05	2,214	$27.00	7,695	No	4	M	Direct
Common Stock	Acquisiton	2021-01-05	1,668	$27.60	9,363	No	4	M	Direct
Common Stock	Acquisiton	2021-01-05	2,082	$46.00	11,445	No	4	M	Direct
Common Stock	Acquisiton	2021-01-05	6,249	$5.95	17,694	No	4	M	Direct
Common Stock	Disposition	2021-01-05	3,700	$110.25	13,994	No	4	S	Direct
Common Stock	Disposition	2021-01-05	4,164	$111.19	9,830	No	4	S	Direct
Common Stock	Disposition	2021-01-05	4,194	$112.19	5,636	No	4	S	Direct
Common Stock	Disposition	2021-01-05	3,500	$113.29	2,136	No	4	S	Direct
Common Stock	Disposition	2021-01-05	1,500	$114.25	636	No	4	S	Direct
Common Stock	Disposition	2021-01-05	349	$115.11	287	No	4	S	Direct
Common Stock	Acquisiton	2021-01-05	1,149	$5.95	1,436	No	4	M	Direct
Common Stock	Disposition	2021-01-05	59	$116.24	1,377	No	4	D	Direct
Common Stock	Disposition	2021-01-05	584	$116.24	793	No	4	F	Direct
Common Stock	Disposition	2021-01-07	506	$124.17	287	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	D	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-05	394	$0.00	394	$27.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-05	2,214	$0.00	2,214	$27.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-05	1,668	$0.00	1,668	$27.60
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-05	2,082	$0.00	2,082	$46.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-05	6,249	$0.00	6,249	$5.95
Common Stock	Stock Appreciation Right	Disposition	2021-01-05	1,149	$0.00	1,149	$5.95

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2026-11-14	No	4	M	Direct
0	2026-11-14	No	4	M	Direct
5,009	2027-12-15	No	4	M	Direct
12,507	2028-12-13	No	4	M	Direct
68,751	2029-09-26	No	4	M	Direct
12,651	2029-09-26	No	4	M	Direct

Footnotes

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.72 to $110.65,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.73 to $111.70,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.72,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.74 to $113.70,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.76,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.06 to $115.15,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reporting person received 506 shares of common stock upon the net exercise of 1,149 stock appreciation rights. The reporting person forfeited 59shares of common stock underlying the stock appreciation rights representing the base value and 584 shares of common stock underlying the stockappreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on January 5, 2021 of $116.24.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.03 to $124.57,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of Novavax, Inc.'s common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Novavax Inc.'s common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 2,084 shares were cancelled.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26,2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.